9 8 月, 2018 11:51 上午發表 femtopath01在〈Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab〉中留言功能已關閉
<Abstract> Alt...
4 1 月, 2018 2:09 下午發表 femtopath01在〈The cutoff limit of reference intervals for mutant KRAS was determined to be ~ 0.09% based on samples from healthy individuals〉中留言功能已關閉
<Title> An im...
12 11 月, 2017 11:05 下午發表 femtopath01在〈Small Cell Carcinoma of the Urinary Bladder and Implications for Diagnosis, Prognosis, and Treatment〉中留言功能已關閉
<Ab...
10 8 月, 2017 4:55 下午發表 femtopath01在〈Clarity™ digital PCR system: a novel platform for absolute quantification of nucleic acids〉中留言功能已關閉
<Abstract> In ...
9 8 月, 2017 2:50 下午發表 femtopath01在〈Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients〉中留言功能已關閉
Check our TP53 mutat...
24 7 月, 2017 11:47 上午發表 femtopath01在〈Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.〉中留言功能已關閉
<Title> Immuno...
15 5 月, 2017 10:09 上午發表 femtopath01在〈British Society of Gastroenterology position statement on serrated polyps in the colon and rectum〉中留言功能已關閉
<Abstract> Ser...
4 5 月, 2017 9:38 上午發表 femtopath01在〈A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome〉中留言功能已關閉
<Title> A tail...
2 2 月, 2017 5:49 下午發表 femtopath01在〈Study provides link between common mutations in blood cells of older adults and atherosclerosis〉中留言功能已關閉
<Title> Study ...
17 2 月, 2016 9:43 上午發表 femtopath01在〈Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer〉中留言功能已關閉
<title> Phase ...